What is Pembrolizumab?

Pembrolizumab is a type of targeted therapy called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the PD-1 protein on the surface of immune cells called T cells. Binding to PD-1 blocks this inhibitory pathway, causing a physiological shift toward immune reactivity and enhancing tumor immune surveillance and anti-tumor immune responses. It works by stopping cancer cells from suppressing the immune system.

Pembrolizumab is used to treat various types of cancer, including metastatic melanoma, non-small cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin lymphoma. Pembrolizumab can cause immune-mediated adverse reactions in any organ system or tissue, including hepatitis, nephritis, and pneumonitis, and patients should be carefully monitored at baseline (including laboratory assessment of liver, renal, and thyroid function) and periodically throughout treatment for emerging immune-mediated reactions.

PembrolizumabThe original drug is already on the market in China. SpecificationsThe price per box of 100mg/4ml may be around RMB 15,000. This drug is a strictly controlled drug and has not yet been included in medical insurance. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.